To investigate the role of FADD (Fas-associated protein with death domain) in Fas and tumor necrosis factor receptor 1 (TNFR1)-mediated hepatic injury and inflammatory response in vivo.
Objective
To investigate the role of FADD (Fas-associated protein with death domain) in Fas and tumor necrosis factor receptor 1 (TNFR1)-mediated hepatic injury and inflammatory response in vivo.
Summary Background Data
Fas and TNFR1 are cell surface molecules that trigger apoptosis or inflammation on engagement by a specific ligand or antibody. FADD is recruited to the cytoplasmic domain of these receptors on their activation and works as a common mediator to induce apoptosis. It is known that a blockade of FADD can inhibit apoptosis mediated by Fas or TNFR1 in vitro. However, it is not known whether the blockade can prevent organ injury and whether the inflammatory cascade is affected in vivo.
Methods
A FADD deletion mutant lacking the death effector domain was introduced into mice by transduction with an adenovirus vector, and the effect of this FADD dominant negative mutant was examined in several liver injury models.
Results
Hepatic injury induced by anti-Fas monoclonal antibody or tumor necrosis factor (TNF)-␣ plus D-galactosamine was markedly ameliorated by the FADD dominant negative transduction, which abrogated the death rate. Further, the FADD dominant negative transduction efficiently blocked T cellmediated concanavalin A-induced hepatitis while not affecting TNF-␣ production or TNF-␣-induced nuclear factor-B activation in the liver.
Conclusions
These results provide the basis for a novel therapeutic modality in which an unfavorable apoptotic process can be inhibited without affecting a favorable response for liver regeneration; this would be relevant to the clinical treatment of acute and chronic liver diseases as well as to some inflammatory disorders with hypercytokinemia, such as sepsis.
Cytokines play important roles in various pathophysiologic states. It is well known that several cytokines, such as tumor necrosis factor (TNF)-␣ and Fas ligand (FasL), have hepatotoxicity and can cause hepatic damage in clinical and experimental situations. 1 In some animal models, these molecules have been implicated in hepatic injury induced by entero-or endotoxemia, as well as by cytotoxic T cells against hepatitis virus.
2-7 We and other groups have indicated that both TNF-␣ and FasL are involved in a T cellmediated concanavalin A (Con A)-induced hepatitis model. 8 -11 These molecules have also been implicated in the pathogenesis of viral hepatitis or Wilson disease.
and Fas, belong to the TNFR family and mediate apoptosis on engagement by natural ligands or agonistic antibodies. 15 They are expressed in a variety of tissues and cells, including the liver and hepatocytes. Apoptosis mediated by these receptors is important in various biologic processes, such as tissue injury, protection against microbes, lymphocyte homeostasis, and immune privilege. [15] [16] [17] The intracellular mechanisms constituting the Fas and TNFR1-induced apoptotic pathway are initiated by receptor clustering. Recently, the yeast two-hybrid strategy allowed the identification of an adaptor molecule called FADD (Fas-associated protein with death domain), which contains a death domain, homologous to that in the cytoplasmic domains of Fas and TNFR1, at its C terminus. 18, 19 FADD is recruited to Fas on ligation of FasL via interaction of its death domain with that of Fas. 20 The interaction of FADD and Fas unmasks the N-terminal death effector domain (DED) of FADD, allowing it to recruit caspase-8 to the Fas signaling complex and thereby activating the caspase cascade leading to cell death. 21, 22 When TNFR1 is activated, TRADD (TNFR1-associated death domain protein) binds to TNFR1. 23 FADD can bind to TRADD through interaction between their death domains. 24 Therefore, Fas and TNFR1 use FADD as a common signal transducer and share the signaling machinery downstream of FADD.
Tumor necrosis factor-␣ not only induces apoptosis but also activates a transcriptional factor nuclear factor (NF)-B. The activation of NF-B is mediated by TNF receptorassociated factor (TRAF) 2, which also binds to TRADD, 25 and is involved in various biologic responses, including cellular proliferation, survival, and liver regeneration. [25] [26] [27] [28] [29] It has been shown in in vitro studies that dominant negative inhibition of FADD by an N-terminally truncated FADD mutant lacking the DED blocked TNF-␣-induced apoptosis without affecting NF-B activation. 24, 30 These findings prompted us to investigate the protective effect of the FADD dominant negative (FADD-DN) mutant on Fas-and TNFR1-mediated liver injury in vivo. In this study, we found for the first time that expression of FADD-DN in the liver efficiently blocked Fas-and TNFR1-mediated hepatic injury in vivo without loss of NF-B activation. The clinical relevance of this finding is discussed.
METHODS

Construction of FADD-DN
The cDNA encoding full-length FADD was kindly provided by Dr. D. V. Goeddel (Tularik Inc., South San Francisco, CA). To make FADD-DN, a deletion mutant of FADD lacking 79 N-terminal amino acids was constructed by polymerase chain reaction (PCR) as previously described. 24 This FADD-DN was able to interact with Fas and TRADD but did not initiate apoptosis. 19, 24, 30, 31 
Adenovirus Vectors
The replication-defective recombinant adenovirus vectors Ad.FADD-DN (adenovirus vector containing mouse FADD-DN cDNA driven by cytomegalovirus [CMV] promoter), Ad.LacZ (adenovirus vector containing the Escherichia coli LacZ gene encoding ␤-galactosidase, driven by CMV promoter), and Ad.Null (adenovirus vector containing no exogenous gene) were constructed by homologous recombination as described previously. 32 Adenovirus vectors were propagated in human embryonic kidney cell line 293 (American Type Culture Collection, Rockville, MD), purified by CsCl 2 gradient centrifugation and dialysis against virus suspension buffer (10 mmol/L Tris-HCl [pH 7.4], 1 mmol/L MgCl 2 , 10% glycerol), and stored at Ϫ80°C as previously described. 33 Titer of the virus stock was determined by plaque assay using 293 cells. 34 
␤-Galactosidase and FADD-DN Expression in the Liver
To evaluate the efficacy of gene transduction to mouse liver by the adenovirus vector, histochemical analysis was performed. Frozen sections of the livers obtained from mice that had been intravenously injected with 1 ϫ 10 9 plaqueforming unit (pfu) of the Ad.LacZ or Ad.Null were stained with 5 mmol/L K 4 Fe (CN) 6 , 5 mmol/L K 3 Fe(CN) 6 (Sigma, St. Louis, MO) and 100 g/mL X-gal reagent (Boehringer Mannheim, Mannheim, Germany) for 3 hours at 37°C to detect the presence of E. coli LacZ gene-derived ␤-galactosidase. 35 Some frozen samples of the liver were used for reverse transcription-PCR analysis to evaluate FADD-DN expression. Total RNA was isolated from the liver using TRISOLV (BIOTECX, Houston, TX) according to the manufacturer's instructions. First-strand cDNA synthesis and PCR were performed as previously described. 10 The PCR primers for endogenous FADD and transduced FADD-DN were 5' GCACTCGAGATGGACGACTTCGAGGCGG 3' and 5' GATGCGGCCGCTCAGGGTGTTTCTGAGGAAGA 3'. The 5' primer for the CMV promoter region was 5' TCT-CACTCTTGCTCACAG 3'. The PCR primers for ␤-actin were 5' GTGGGCCGCTCTAGGCACCAA 3' and 5' CTCTT-TGATGTCACGCACGATTTC 3'. The PCR products were resolved on 1.0% agarose gel and visualized by ethidium bromide staining.
Animal Experiments
Five-week-old male C57BL/6 (B6) mice were purchased from SLC (Hamamatsu, Japan). Mice were injected intravenously via the tail vein with 1 ϫ 10 9 pfu of the adenovirus vectors. At various time points after the adenovirus injection, some mice were intravenously injected with 20 g of a purified hamster monoclonal antibody against mouse Fas (Jo2, Pharmingen, San Diego, CA), 100 ng of mouse TNF-␣ (Pharmingen) and 20 mg of D-galactosamine (D-gal, WAKO, Tokyo, Japan), or 15 mg/kg of Con A (Sigma). These three hepatic injury models have been well established. 36 -39 To prevent Con A-induced hepatitis, some mice were injected with 500 g anti-TNF-␣ mAb (MP6-XT22, Pharmingen) 30 minutes before the Con A injection. After these treatments, the survival of mice was observed and the extent of liver injury was measured by serum transaminase levels. Transaminase (AST and ALT) activities in the serum were measured by the standard photometric method using a Hitachi type 7350 automatic analyzer (Hitachi, Tokyo, Japan). Serum levels of TNF-␣ and interleukins 1 and 6 after Con A injection were determined by enzyme-linked immunosorbent assay (ELISA) kits (Endogen, Boston, MA). Liver samples from individual mice were fixed in 10% formalin and embedded in paraffin. Five-micrometer sections were stained with hematoxylin and eosin.
Gel Shift Assay for NF-B Activation
Six hours after the Con A injection, liver samples from individual mice were obtained. Nuclear extracts were prepared and gel shift assay was performed with an oligonucleotide specific for NF-B (5'-GGG-ATC-GAG-GGG-ACT-TTC-CCT-AGC-3') as described previously. 40 
Statistical Analysis
Statistical analysis was performed using the Student t test. P Ͻ .05 was considered significant.
RESULTS
Adenovirus-Mediated Gene Transfer to Liver
To evaluate the feasibility of adenovirus-mediated gene transfer to the liver, 1 ϫ 10 9 pfu of the adenovirus vector containing the E. coli lacZ gene encoding ␤-galactosidase (Ad.LacZ) or the control (Ad.Null) was intravenously injected into B6 mice via the tail vein. The liver was removed after 24, 48, or 72 hours, and the expression of ␤-galactosidase was assessed by X-gal staining. At 24 hours after the administration of Ad.LacZ, expression of transduced ␤-galactosidase was broadly observed in the liver, covering approximately 80% of hepatocytes, and it was maintained at 48 or 72 hours (data not shown). In contrast, no significant X-gal staining was observed after the administration of Ad.Null (data not shown). These results indicate that the intravenous injection of adenoviral vector is an efficient means of gene transfer to the liver.
Next, we examined FADD-DN expression in the liver 24 hours after intravenous injection of 1 ϫ 10 9 pfu of Ad.Null or Ad.FADD-DN by reverse transcriptase-PCR. By using PCR primers for the 5' and 3' ends of FADD-DN, a strong band representing a mixture of endogenous FADD and exogenously transduced FADD-DN was observed after the Ad.FADD-DN administration, and a weak band representing endogenous FADD was observed after the Ad.Null administration (Fig. 1) . With primers for CMV promoter and the 3' end of FADD-DN, expression of FADD-DN was detectable in the liver after injection of Ad.FADD-DN but not Ad.Null. These results indicate that the intravenous administration of Ad.FADD-DN leads to the efficient expression of FADD-DN in the liver.
Prevention of Fas-and TNFR1-Mediated Liver Injury by Administration of Ad.FADD-DN
Previous in vitro studies showed that the FADD-DN remained able to interact with the death domain of Fas but could not initiate apoptosis because it lacks the DED and, thus, acted as a dominant negative inhibitor against the FADD-mediated apoptosis. 19, 31 We then investigated whether FADD-DN could prevent Fas-induced liver injury in vivo. Twenty g anti-mouse Fas monoclonal antibody (Jo2), which has been reported to induce a lethal liver injury, 36 was intravenously injected into B6 mice that had been intravenously administered with 1 ϫ 10 9 pfu of Ad.Null or Ad.FADD-DN 24 hours before. Acute lethal hepatic failure occurred within 12 hours in all control mice given Ad.Null. In contrast, all the mice (n ϭ 8) given Ad.FADD-DN survived over 48 hours ( Fig. 2A, P Ͻ .001 ). These eight mice were still alive and exhibited no manifestation of disease 3 months after the experiment. Next, we injected TNF-␣ and D-gal, which has been shown to induce TNFR1-mediated liver injury. 38 The pretreatment with Ad.FADD-DN also completely blocked the TNF-␣-induced lethality (Fig. 2B) . Histologic examination of the livers from the Ad.Null-treated mice after the anti-Fas monoclonal antibody or TNF-␣ injection showed extensive lesions characterized by massive hepatocyte destruction with frequent nuclear chromatin condensation, indicative of apoptosis, and by intraparenchymatous hemorrhages in the areas with the most extensive hepatocyte damage. In contrast, the livers of mice treated with Ad.FADD-DN showed few histologic changes, preservation of tissue architecture, no hemorrhages, and only occasional swelling of some hepatocytes (data not shown). These results indicate that the administration of Ad.FADD-DN efficiently prevents Fas-and TNFR1-mediated liver injury in vivo.
To determine the earliest time point and duration of protective effect after FADD-DN transduction, we challenged the mice with anti-Fas monoclonal antibody periodically after Ad.FADD-DN administration. When challenged at 12 hours after the Ad.FADD-DN administration, all the mice (4/4) survived. However, at 6 hours after administration, only half of the mice (2/4) survived, and at 3 hours after administration, all the mice (n ϭ 5) died (data not 5 Therapeutic Blockade of FADD shown). These results indicate that a period of at least 6 hours is necessary for Ad.FADD-DN to prevent Fas-mediated liver injury. As to the duration, we delayed the anti-Fas monoclonal antibody challenge in 5-day intervals. When challenged up to 20 days after the Ad.FADD-DN administration, all the mice (n ϭ 5 at each time point) survived, but at 25 days after administration, only 20% of the mice survived. At 30 days after administration, no protective effect of Ad.FADD-DN remained (data not shown). These results indicate that the effect of Ad.FADD-DN to prevent Fas-mediated liver injury lasted about 3 weeks after administration but was abolished thereafter. 
Prevention of Con A-Induced Liver Injury by Administration of Ad.FADD-DN
We and others have shown that both TNF-␣ and FasL are critically involved in Con A-induced hepatitis.
10,11 Thus, we examined whether the administration of Ad.FADD-DN could prevent Con A-induced hepatitis. When 15 mg/kg Con A was intravenously injected into untreated B6 mice, a striking increase in serum transaminase levels was observed (Fig. 3) . Histologic examination showed a massive infiltration of mononuclear and polymorphonuclear cells and degenerative changes in hepatocytes in the liver, as previously reported 10 (data not shown). Similar liver injury was observed in the Ad.Null-treated mice after Con A injection, based on the increased serum transaminase levels (see Fig.  3 ) and the histologic changes (not shown). However, in the Ad.FADD-DN-treated mice, the Con A-induced liver injury was remarkably ameliorated based on the serum transaminase levels and histologically. These results indicate that Ad.FADD-DN treatment can block the T cell-mediated liver injury induced by Con A, in which both TNF-␣ and FasL are critically involved. Pretreatment with anti-TNF-␣ monoclonal antibody also prevented Con A-induced hepatitis, as previously reported.
-10
Effect of FADD on Intrahepatic Activation of NF-B After Con A Injection
It has been reported that Con A injection into mice induced TNF-␣-dependent activation of NF-B in hepatocytes. 41 Thus, we next examined the effect of Ad.FADD-DN treatment on intrahepatic activation of NF-B after Con A injection. Nuclear extracts prepared from livers of the mice that had been treated with Ad.Null or Ad.FADD-DN and then injected with Con A were assessed for NF-B activation by the gel shift assay. Con A injection induced a marked nuclear accumulation of NF-B in hepatocytes from untreated mice (not shown) as reported, 41 as well as in those from the Ad-.Null-treated mice (Fig. 4) . Although Ad.FADD-DN treatment efficiently prevented Con A-induced hepatocyte damage, as described above (see Fig. 3 ), it did not influence NF-B activation. In contrast, anti-TNF-␣ monoclonal antibody treatment almost completely blocked NF-B activation. These results indicate that Ad.FADD-DN treatment selectively blocked the apoptotic pathway but not the NF-B activation pathway after TNFR1 stimulation in vivo, although anti-TNF-␣ monoclonal antibody treatment blocked both pathways. We also Nuclear factor (NF)-B activation in the liver after concanavalin A (Con A) injection. B6 mice were pretreated with Ad.Null, Ad.FADD-DN, or anti-tumor necrosis factor-␣ monoclonal antibody (anti-TNF-␣ mAb), and then challenged with Con A as described in Figure 3 . Six hours later, the livers were obtained, and nuclear extracts were subjected to the NF-B-specific gel shift assay. Similar results were obtained in three independent experiments.
Therapeutic Blockade of FADD examined serum levels of TNF-␣ and interleukin 1 and 6 after Con A injection. Serum TNF-␣ levels in the untreated mice showed a striking increase 45 minutes after the Con A injection (not shown) as reported, 10 and the Ad.Null-treated mice showed a similar increase (Fig. 5) . In the Ad.FADD-DN treated mice, TNF-␣ levels were comparable to those in the Ad.Null-treated mice. However, in the mice treated with anti-TNF-␣ monoclonal antibody, serum TNF-␣ could not be detected by ELISA. These results indicate that Ad.FADD-DN treatment did not block TNF-␣ production after Con A injection. In contrast, pretreatment with FADD-DN partially decreased interleukin 1 and 6 levels. The peak response of interleukins 1 and 6 was detected around 3 to 4 hours after Con A injection, significantly later than that of TNF-␣ (~1 hour), 8 and the blood samples were obtained at those times, respectively.
DISCUSSION
In this study, we showed that the liver-directed transgene of a truncated form of FADD, which acts dominant negatively against the proapoptotic function of FADD, efficiently ameliorated Fas-and TNFR1-mediated liver injury in mice. Because FasL and TNF-␣ are likely to play a critical role in some forms of hepatic disorder, 2,4 -11 even in clinical situations, [12] [13] [14] gene therapy that transduces FADD-DN into the liver may represent a new therapeutic strategy against life-threatening liver diseases such as fulminant hepatitis.
The protective effect of Ad.FADD-DN disappeared within 3 weeks after its administration, presumably as a result of immunologic elimination of the adenovirus, as previously shown. 42 This spontaneous disappearance of FADD-DN would be advantageous in the transient treatment of acute hepatic failure, because it has been shown that Fas-null mice, established by gene targeting, had hyperplasia of the liver from a defect in elimination of senescent hepatocytes, suggesting that the Fas/FasL system is involved in homeostasis of the liver. 43 Thus, an everlasting FADD-DN expression in the liver might cause an undesirable side effect such as accumulation of transformed hepatocytes. Further, by using FADD-null mice, it has been shown that FADD is involved not only in apoptosis but also in embryonic development and T-cell activation. 44, 45 Therefore, the transient nature of FADD-DN expression in the liver after Ad.FADD-DN administration would be preferable for therapeutic use against acute hepatic diseases.
Recently, Tsutsui et al 46 showed that interleukin 18 secreted by FasL-stimulated macrophages plays a critical role in FasL-induced liver injury. This processing of interleukin 18 was dependent on caspases, but it is still unclear whether this process is mediated by FADD. If the interleukin 18 secretion from FasL-stimulated macrophages is indeed mediated by FADD, FADD-DN expression in hepatic macrophages, Kupffer cells, or both might inhibit the interleukin 18 secretion from these cells, thus also leading to the amelioration of liver injury. Further studies are needed to address this possibility.
Tumor necrosis factor-␣ activates not only the apoptotic pathway but also NF-B, which attenuates the proapoptotic action of TNF-␣. [25] [26] [27] It has been shown that knockout mice lacking the RelA component of NF-B had massive liver degeneration resulting from hypersensitivity of hepatocytes to endogenous TNF-␣-induced apoptosis, substantiating the important role of NF-B for protection of hepatocytes from TNF-␣ cytotoxicity. 29, 47 Moreover, both TNF-␣ and NF-B have been implicated in the proliferation of hepatocytes during liver regeneration. 28, 48 In this study, we showed that FADD-DN prevented hepatocyte damage but not NF-B activation in the liver after Con A injection. This feature of FADD-DN would be beneficial for facilitating NF-Bmediated liver regeneration in therapeutic treatment of acute and chronic liver injury. In contrast, anti-TNF-␣ monoclonal antibody treatment abrogated not only hepatocyte damage but also NF-B activation, which might be unfavorable for repair of liver damage. This may also be relevant to the clinical treatment of other disorders, such as sepsis. Previous experimental and clinical studies have implicated both TNF-␣ and interleukin 1␤ in the pathogenesis of septic shock. Large-scale, randomized clinical trials using antibody to TNF-␣, soluble TNF receptors, or interleukin 1 receptor antagonist have been performed in patients with sepsis. 49 -51 However, those clinical trials failed to show a significant benefit. Further, in the study with soluble TNF receptors, the death rate was increased with higher doses of the soluble TNF receptor among patients with gram-positive infections. 51 The reason for such an unfavorable effect has not been clarified. However, one likely explanation is that the complete removal of TNF-␣ or interleukin 1 was not favorable in patients with sepsis, because it might also abrogate the beneficial effects of these cytokines against bacterial infection. In this respect, it is noteworthy that a clinical trial with interferon-␥ in patients with sepsis and deactivated monocytic function resulted in an increase of plasma TNF-␣ levels and ameliorated sepsis in eight of nine patients. 52 Therefore, an effective treatment of sepsis may be achieved by selective inhibition of the apoptotic pathway without abolishing the beneficial effects of these proinflammatory cytokines, which are at least in part mediated by NF-B activation. In this context, the blockade of FADD, as shown in this study, could be an effective therapeutic strategy not only for liver diseases but also for sepsis and other diseases in which Fas and TNFR1 are implicated. In this study, we also found that pretreatment with FADD-DN partially decreased serum levels of interleukin 1 and 6 but not TNF-␣ after Con A injection. The peak response of interleukins 1 and 6 occurred later (~3-4 hours) than that of TNF-␣ (~1 hour) after Con A injection. 8 Thus, it is likely that inhibition of apoptosis by FADD-DN in the early phase prevented the secondary response of Con A hepatitis, in which interleukins 1 and 6 have been reported to be involved. 8, 9 However, a substantial amount of interleukins 1 and 6 was still produced. Therefore, it seems that the administration of FADD-DN can prevent overproduction of some cytokines that may play some detrimental roles, maintaining the proinflammatory cytokine cascade. In conclusion, the blockade of FADD may be clinically applied for inhibiting cell death in injured organs while preserving a beneficial immune response for protection, accompanied by other anticytokine therapy.
